A citation-based method for searching scientific literature

Ruqin Chen, Rami Manochakian, Lauren James, Abdel-Ghani Azzouqa, Huashan Shi, Yan Zhang, Yujie Zhao, Kexun Zhou, Yanyan Lou. J Hematol Oncol 2020
Times Cited: 55







List of co-cited articles
166 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
16

Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
14

The biology and management of non-small cell lung cancer.
Roy S Herbst, Daniel Morgensztern, Chris Boshoff. Nature 2018
12

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
10

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
10

Oncology meets immunology: the cancer-immunity cycle.
Daniel S Chen, Ira Mellman. Immunity 2013
9

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.
Min Yuan, Li-Li Huang, Jian-Hua Chen, Jie Wu, Qing Xu. Signal Transduct Target Ther 2019
192
9

Pembrolizumab for the treatment of non-small-cell lung cancer.
Edward B Garon, Naiyer A Rizvi, Rina Hui, Natasha Leighl, Ani S Balmanoukian, Joseph Paul Eder, Amita Patnaik, Charu Aggarwal, Matthew Gubens, Leora Horn,[...]. N Engl J Med 2015
9

Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Narjust Duma, Rafael Santana-Davila, Julian R Molina. Mayo Clin Proc 2019
555
7

Non-small cell lung cancer: current treatment and future advances.
Cecilia Zappa, Shaker A Mousa. Transl Lung Cancer Res 2016
758
7

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
7

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi,[...]. N Engl J Med 2018
7

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Julian R Molina, Ping Yang, Stephen D Cassivi, Steven E Schild, Alex A Adjei. Mayo Clin Proc 2008
7


Non-small-cell lung cancers: a heterogeneous set of diseases.
Zhao Chen, Christine M Fillmore, Peter S Hammerman, Carla F Kim, Kwok-Kin Wong. Nat Rev Cancer 2014
960
5

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer.
Qiming Wang, Sen Yang, Kai Wang, Shi-Yong Sun. J Hematol Oncol 2019
99
5

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.
Min Yuan, Li-Li Huang, Jian-Hua Chen, Jie Wu, Qing Xu. Signal Transduct Target Ther 2019
109
5

Lung cancer: current therapies and new targeted treatments.
Fred R Hirsch, Giorgio V Scagliotti, James L Mulshine, Regina Kwon, Walter J Curran, Yi-Long Wu, Luis Paz-Ares. Lancet 2017
5

Global Epidemiology of Lung Cancer.
Julie A Barta, Charles A Powell, Juan P Wisnivesky. Ann Glob Health 2019
463
5

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Lindeman, Titus J Boggon,[...]. Science 2004
5

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Roy S Herbst, Giuseppe Giaccone, Filippo de Marinis, Niels Reinmuth, Alain Vergnenegre, Carlos H Barrios, Masahiro Morise, Enriqueta Felip, Zoran Andric, Sarayut Geater,[...]. N Engl J Med 2020
400
5

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC.
Mengke Niu, Ming Yi, Ning Li, Suxia Luo, Kongming Wu. Exp Hematol Oncol 2021
27
11

Nano based drug delivery systems: recent developments and future prospects.
Jayanta Kumar Patra, Gitishree Das, Leonardo Fernandes Fraceto, Estefania Vangelie Ramos Campos, Maria Del Pilar Rodriguez-Torres, Laura Susana Acosta-Torres, Luis Armando Diaz-Torres, Renato Grillo, Mallappa Kumara Swamy, Shivesh Sharma,[...]. J Nanobiotechnology 2018
5

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
5

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
5

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Tony S K Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M Kowalski, Byoung Chul Cho, Hande Z Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K Laktionov, Igor Bondarenko,[...]. Lancet 2019
5

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Alan Sandler, Robert Gray, Michael C Perry, Julie Brahmer, Joan H Schiller, Afshin Dowlati, Rogerio Lilenbaum, David H Johnson. N Engl J Med 2006
5

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Tony S Mok, Yi-Long Wu, Myung-Ju Ahn, Marina C Garassino, Hye R Kim, Suresh S Ramalingam, Frances A Shepherd, Yong He, Hiroaki Akamatsu, Willemijn S M E Theelen,[...]. N Engl J Med 2017
5

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols,[...]. Lancet 2017
5

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
5

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
5

Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer.
Kohsuke Isomoto, Koji Haratani, Hidetoshi Hayashi, Shigeki Shimizu, Shuta Tomida, Takashi Niwa, Toshihide Yokoyama, Yasushi Fukuda, Yasutaka Chiba, Ryoji Kato,[...]. Clin Cancer Res 2020
67
5

Drug resistance to targeted therapeutic strategies in non-small cell lung cancer.
Wen-Juan Liu, Yue Du, Ru Wen, Ming Yang, Jian Xu. Pharmacol Ther 2020
58
5

Oncogenic pathway signatures in human cancers as a guide to targeted therapies.
Andrea H Bild, Guang Yao, Jeffrey T Chang, Quanli Wang, Anil Potti, Dawn Chasse, Mary-Beth Joshi, David Harpole, Johnathan M Lancaster, Andrew Berchuck,[...]. Nature 2006
5

Update 2020: Management of Non-Small Cell Lung Cancer.
Mariam Alexander, So Yeon Kim, Haiying Cheng. Lung 2020
52
5

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
5

Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer.
D A Fennell, Y Summers, J Cadranel, T Benepal, D C Christoph, R Lal, M Das, F Maxwell, C Visseren-Grul, D Ferry. Cancer Treat Rev 2016
200
3

Non-small-cell lung cancer.
Cesare Gridelli, Antonio Rossi, David P Carbone, Juliana Guarize, Niki Karachaliou, Tony Mok, Francesco Petrella, Lorenzo Spaggiari, Rafael Rosell. Nat Rev Dis Primers 2015
369
3

Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition.
Ming Sun, Xiang-Hua Liu, Ke-Ming Wang, Feng-qi Nie, Rong Kong, Jin-song Yang, Rui Xia, Tong-Peng Xu, Fei-Yan Jin, Zhi-Jun Liu,[...]. Mol Cancer 2014
179
3


First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari,[...]. N Engl J Med 2014
3

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.
A J Schoenfeld, K C Arbour, H Rizvi, A N Iqbal, S M Gadgeel, J Girshman, M G Kris, G J Riely, H A Yu, M D Hellmann. Ann Oncol 2019
145
3


Simultaneous Activation of Induced Heterodimerization between CXCR4 Chemokine Receptor and Cannabinoid Receptor 2 (CB2) Reveals a Mechanism for Regulation of Tumor Progression.
Christopher J Coke, Kisha A Scarlett, Mahandranauth A Chetram, Kia J Jones, Brittney J Sandifer, Ahriea S Davis, Adam I Marcus, Cimona V Hinton. J Biol Chem 2016
60
3

The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.
Sean D McAllister, Liliana Soroceanu, Pierre-Yves Desprez. J Neuroimmune Pharmacol 2015
61
3

Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion.
Mohd W Nasser, Zahida Qamri, Yadwinder S Deol, Diane Smith, Konstantin Shilo, Xianghong Zou, Ramesh K Ganju. PLoS One 2011
63
3

Cannabinoid receptor-2 agonist inhibits macrophage induced EMT in non-small cell lung cancer by downregulation of EGFR pathway.
Janani Ravi, Mohamad Elbaz, Nissar A Wani, Mohd W Nasser, Ramesh K Ganju. Mol Carcinog 2016
44
4

LungCARD - Report on worldwide research and clinical practices related to lung cancer.
Radmila Jankovic, Helena J Goncalves, Milena Cavic, Carla Clemente, Michael Lind, Alexis Murillo Carrasco, Selama Nadifi, Meriem Khyatti, Tumininu Adebambo, Dilshod Egamberdiev. J BUON 2019
8
25

The Endocannabinoid System: A Target for Cancer Treatment.
Chiara Laezza, Cristina Pagano, Giovanna Navarra, Olga Pastorino, Maria Chiara Proto, Donatella Fiore, Chiara Piscopo, Patrizia Gazzerro, Maurizio Bifulco. Int J Mol Sci 2020
50
4

Up-regulation of cyclooxygenase-2 expression is involved in R(+)-methanandamide-induced apoptotic death of human neuroglioma cells.
Burkhard Hinz, Robert Ramer, Karin Eichele, Ulrike Weinzierl, Kay Brune. Mol Pharmacol 2004
83
3


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.